Biosimilars Chemotherapy Pharmacy Technician 
Pharmacy Times
JULY 16, 2025
The SERENA-6 trial used ctDNA monitoring to identify the development of a resistant ESR1 mutation in patients with hormone receptor–positive breast cancer receiving first-line aromatase inhibitor (AI) plus a CDK4/6 inhibitor.
Pharmacy Times
JUNE 27, 2025
Because of its aggressive nature, MCL is typically treated with combination chemotherapy at diagnosis. For this application, the FDA collaborated with the Australian Therapeutic Goods Administration, Health Canada, and Switzerland’s Swissmedic.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmacy Times
JUNE 18, 2025
1 Organizations are taking action to improve care for everyone, but pharmacists and pharmacy technicians may be unaware of their opportunities to advance SDOH. Wick, MBA, RPh, FASCP, is the director of the Office of Pharmacy Professional Development at the University of Connecticut in Storrs. About the Author Jeannette Y.
Pharmacy Times
AUGUST 8, 2025
2 In patients who had received prior platinum-based chemotherapy but had not been treated with a HER2-targeted TKI or antibody-drug conjugate (ADC; n = 71), the ORR was approximately 75% (95% CI, 63–83), with 58% of patients achieving a DOR of at least 6 months.
Pharmacy Times
JUNE 9, 2025
doi:10.1056/NEJMoa1901963 Newsletter Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights. N Engl J Med. 2019;380:2020-2030. Subscribe Now!
Pharmacy Times
JUNE 12, 2025
The session, which was entitled “Decoding the Logic: An Overview of Biologics and Biosimilars,” described clinical applications and economic impacts associated with biologics and biosimilars over the last 10 to 15 years, as well as outlined what skills effectively contribute to their management and understanding.
Pharmacy Times
JUNE 11, 2025
Approximately 40% to 80% of patients with cancer who are assigned female at birth face possible infertility as a result of their cancer treatments, such as chemotherapy, radiation, and surgery. An additional 15% to 30% of cancer survivors who are assigned male at birth also face infertility as a result of chemotherapy.
Expert insights. Personalized for you.
Let's personalize your content